Red-flags for cardiac amyloidosis in real life of an internal medicine department

17 May 2025 (08:00 - 12:45)

Organised by:

Sign in for access options

Sign in to view the resources

Sign in for access options

About the speaker

Doctor Isabel Fiteni Mera

HOSPITAL ROYO VILLANOVA, Zaragoza (Spain)

8 More presentations in this session

Presentation thumbnail

Effects of tafamidis on pacemaker therapy

Doctor M. Figueiredo (Barreiro, PT)

Abstract Slides Video

Presentation thumbnail

Clinical characteristics, mortality outcomes and survival predictors of transthyretin cardiac amyloidosis in an Asian registry

Doctor V. Putri (Singapore, SG)

Abstract Slides Video

Presentation thumbnail

A descriptive journey through the heart of transthyretin cardiac amyloidosis

Doctor M. Rodrigues Simoes (Coimbra, PT)

Abstract Slides Video

Presentation thumbnail

Diagnostic value of the right ventricular wall thickness and free wall strain ratio in distinguishing hypertrophic cardiomyopathy and wild-type transthyretin cardiac amyloidosis

Doctor E. Mata (Creixomil, PT)

Abstract Slides Video

Presentation thumbnail

Associations between age and sex and cardiovascular outcomes in patients with non-obstructive hypertrophic cardiomyopathy

Doctor P. Gebrehiwet (South San Francisco, US)

Abstract Slides Video

Access the full session

Session thumbnail

ePosters in myocardial disease (2)

The Event

Event poster

Heart Failure 2025

17 May - 20 May 2025

You may be interested in

Congress Presentation

Investigation of the prevalence of cardiac amyloidosis among patients with echocardiographically verified myocardial hypertrophy of unknown etiology

Congress Presentation

Validation of red flags in cardiac amyloidosis across diagnostic modalities.

Congress Presentation

Restrictive cardiomyopathy: following the red flags to reach the diagnosis

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources